scispace - formally typeset
K

Kathleen C. Day

Researcher at University of Michigan

Publications -  32
Citations -  2622

Kathleen C. Day is an academic researcher from University of Michigan. The author has contributed to research in topics: Bladder cancer & Prostate cancer. The author has an hindex of 21, co-authored 32 publications receiving 2447 citations. Previous affiliations of Kathleen C. Day include Monsanto & Washington University in St. Louis.

Papers
More filters
Journal ArticleDOI

Targeted gold nanorod contrast agent for prostate cancer detection by photoacoustic imaging

TL;DR: Combining ultrasound with contrast agent based photoacoustic imaging is proposed as a visual tool to compound molecular and structural information for early stage prostate cancer detection.
Journal ArticleDOI

HER2 Drives Luminal Breast Cancer Stem Cells in the Absence of HER2 Amplification: Implications for Efficacy of Adjuvant Trastuzumab

TL;DR: It is shown that HER2 is selectively expressed in and regulates self-renewal of the cancer stem cell (CSC) population in estrogen receptor-positive, HER2(-) luminal breast cancers, and a CSC model in which maximal clinical benefit is achieved when CSC targeting agents are administered in the adjuvant setting is supported.
Journal ArticleDOI

Indocyanine-green-embedded PEBBLEs as a contrast agent for photoacoustic imaging.

TL;DR: Initial in vitro characterization shows high contrast and high efficiency for binding to prostate cancer cells, and ICG-embedded ormosil PEBBLEs showed improved stability in aqueous solution compared with free ICG dye.
Journal ArticleDOI

The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation.

TL;DR: Evidence is provided that ADAM15 catalyzes the cleavage of E-cadherin to generate a soluble fragment that in turn binds to and stimulates ErbB receptor signaling, supporting both cell migration and proliferation.
Journal ArticleDOI

The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells.

TL;DR: A novel mechanism by which E-cadherin is functionally inactivated through calpain-mediated proteolysis is demonstrated and suggests that E- cadher in is targeted by calpain during the tumorigenic progression of prostate cancer.